Incidentally discovered pituitary masses: pituitary incidentalomas

References

• Tenner E. Why Things Bite Back: Technology and the Revenge of Unintended Consequences. Knopf AA (Ed.) NY, USA (1996).
   Google Scholar
• Chidiac RM, Aron DC. Incidentalomas: a disease of modern technology. Endocrinol. Metab. Clin. N. Am.26, 233–253 (1997).
   PubMedGoogle Scholar
• Lau J, Balk E, Rothberg M et al. Management of clinically inapparent adrenal mass. Evidence Report/Technology Assessment (number 56). AHRQ Publication Rockville, MD, USA (2002).
   Google Scholar
• Molitch ME, Russell EJ. The pituitary “incidentaloma”. Ann. Intern. Med.112, 925–931 (1990).
   PubMed Web of Science ®Google Scholar
• Molitch M. Non functioning pituitary tumors and pituitary incidentalomas. Endocrinol. Metab. Clin. N. Am.37, 151–171 (2008).
   PubMed Web of Science ®Google Scholar
• Serhal D, Weil R, Hamrahian A. Evaluation and management of pituitary incidentalomas. Cleve. Clin. J. Med.75, 793–801 (2008).
   PubMedGoogle Scholar
• Klibanski A, Zervas NT, Kovacs K, Ridgeway EC. Clinically silent hypersecretion of growth hormone in patients with pituitary tumors. J. Neurosurg.66, 806–811 (1987).
   PubMed Web of Science ®Google Scholar
• Aron DC. The adrenal incidentaloma: disease of modern technology and public health problem. Rev. Endocr. Metab. Disord.2, 335–342 (2001).
   PubMedGoogle Scholar
• Aron DC. Endocrine incidentalomas. Endocrinol. Metab. Clin. North Am.29, 1–238 (2002).
   Google Scholar
• King JT Jr, Justice A, Aron DC. Management of incidental pituitary microadenomas: a cost-effectiveness analysis. J. Clin. Endocrinol. Metab.82, 3625–3632 (1997).
   PubMed Web of Science ®Google Scholar
• Krikorian A, Aron DC. Pituitary incidentalomas: revisiting an old acquaintance. Endocrinol. Metab. Clin. North Am.2, 1–8 (2006).
   Google Scholar
• Mavrakis A, Tritos N. Diagnostic and therapeutic approach to pituitary incidentalomas. Endocr. Pract.10, 438–444 (2004).
   PubMedGoogle Scholar
• Howlett TA, Como J, Aron DC. Management of pituitary incidentalomas. A survey of British and American endocrinologists. Endocrinol. Metab. Clin. N. Am.29, 223–230 (2000).
   PubMed Web of Science ®Google Scholar
• Molitch M. Clinical review 65 evaluation and treatment of the patient with a pituitary incidentaloma. J. Clin. Endocrinol. Metab.80, 3–6 (1995).
   PubMed Web of Science ®Google Scholar
• Sam S, Molitch M. The pituitary mass: diagnosis and management. Rev. Endocr. Metab. Disord.6, 55–62 (2005).
   PubMed Web of Science ®Google Scholar
• Teramoto A, Hirakawa K, Sanno N, Osamura Y. Incidental pituitary lesions in 1,000 unselected autopsy specimens. Radiology193, 161–164 (1994).
   PubMedGoogle Scholar
• Ezzat S, Asa SL, Couldwell WT et al. The prevalence of pituitary adenomas: a systematic review. Cancer101(3), 613–619 (2004).
   PubMed Web of Science ®Google Scholar
• Rittierodt M, Hori A. Pre-morbid morphological conditions of the human pituitary. Neuropathology27, 43–48 (2007).
   PubMedGoogle Scholar
• Nammour G, Ybarra J, Naheedy M, Romeo J, Aron D. Incidental pituitary macroadenoma: a population-based study. Am. J. Med. Sci.314, 287–291 (1997).
   PubMed Web of Science ®Google Scholar
• Vernooij M, Ikram M, Tanghe H, Vincent A. Incidental findings on brain MRI in the general population. N. Engl. J. Med.357, 1821–1828 (2007).
   PubMed Web of Science ®Google Scholar
• Yue NC Longstreth WT Jr, Elster AD et al. Clinically serious abnormalities found incidentally at MR imaging of the brain: data from the Cardiovascular Health Study. Radiology202, 41–46 (1997).
   PubMedGoogle Scholar
• Wolpert S, Molitch M, Goldman J, Wood J. Size, shape, and appearance of the normal female pituitary gland. Am. J. Roentgenol.143, 377–381 (1984).
   PubMedGoogle Scholar
• Hall WA, Luciano MG, Doppman JL, Patronas NJ, Oldfield EH. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann. Intern. Med.120, 817–820 (1994).
   PubMed Web of Science ®Google Scholar
• Gao R, Isoda H, Tanaka T et al. Dynamic gadolinium-enhanced MR imaging of pituitary adenomas: usefulness of sequential sagittal and coronal plane images. Eur. J. Radiol.39, 139–146 (2001).
   PubMedGoogle Scholar
• Indrajit ICN, Sundar K, Ahmed I. Value of dynamic MRI imaging in pituitary adenomas. Ind. J. Radiol. Imag.11, 185–190 (2001).
   Google Scholar
• Arita K, Tominaga A, Sugiyama K et al. Natural course of incidentally found nonfunctioning pituitary adenoma, with special reference to pituitary apoplexy during follow up examination. J. Neurosurg.104, 884–891 (2006).
   PubMed Web of Science ®Google Scholar
• Johnson MD, Woodburn CJ, Vance M. Quality of life in patients with a pituitary adenoma. Pituitary6, 81–87 (2003).
   PubMedGoogle Scholar
• Karavitaki N, Collison K, Halliday J et al. What is the natural history of nonoperated nonfunctioning pituitary adenomas? Clin. Endocrinol.67, 938–943 (2007).
   PubMedGoogle Scholar
• Cury M, Fernandes J, Machado H et al. Non-functioning pituitary adenomas: clinical feature, laboratorical and imaging assessment, therapeutic management and outcome. Arq. Bras. Endocrinol. Metab.53, 31–39 (2008).
   Google Scholar
• Dekkers O, Hammick M, de Keizer R et al. The natural course of non-functioning pituitary macrodenomas. Eur. J. Endocrinol.156, 217–224 (2007).
   PubMed Web of Science ®Google Scholar
• Fainstein Day P, Guitelman M, Artese R et al. Retrospective multicentric study of pituitary incidentalamos. Pituitary7, 145–148 (2004).
   PubMedGoogle Scholar
• Kastelan D, Korsic M. High prevalence rate of pituitary incidentaloma: is it associated with the age-related decline of the sex hormones levels? Medical Hypotheses69, 307–309 (2007).
   PubMedGoogle Scholar
• Ciccarelli A, Daly A, Beckers A. The epidemiology of prolactinomas. Pituitary8, 3–6 (2005).
   PubMedGoogle Scholar
• Coulter I, Mukerji N, Bradey N, Connolly V, Kane P. Radiologic follow-up of non-functioning pituitary adenomas: rationale and cost effectiveness. J. Neurooncol.93, 157–163 (2009).
   PubMedGoogle Scholar
• Turner H, Stratton I, Byrne J, Adams C, Wass J. Audit of selected patients with nonfunctioning pituitary adenomas treated without irradiation – a follow-up study. Clin. Endocrinol.51, 281–284 (1999).
   PubMed Web of Science ®Google Scholar
• Donovan L, Corenblum B. The natural history of the pituitary incidentaloma. Arch. Intern. Med.155, 181–183 (1995).
   PubMedGoogle Scholar
• Reincke M, Allolio B, Saeger W, Menzel J, Winkelmann W. The ‘incidentaloma’ of the pituitary gland. Is neurosurgery required. JAMA263, 2772–2776 (1990).
   PubMedGoogle Scholar
• Freda P, Post K. Differential diagnosis of sellar masses. Endocrinol. Metab. Clin. N. Am.28, 81–117 (1995).
   Google Scholar
• Ambrosi B, Faglia G; the Multicenter Pituitary Tumor Study Group. Lombardia region. Epidemiology of pituitary tumors. Pituitary adenomas In: New Trends in Basic and Clinical Research. Faglia G, Beck-Peccoz P, Ambrosi B, Travaglini P, Spada A (Eds).Elsevier Science Publishers, NY, USA 159–168 (1991).
   Google Scholar
• Daly A, Rixhon M, Adam C et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liège, Belgium. J. Clin. Endocrinol. Metab.91, 4769–4775 (2006).
   PubMed Web of Science ®Google Scholar
• Golden S, Robinson K, Saldanha I, Anton B, Ladenson P. Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J. Clin. Endocrinol. Metab.94, 1853–1878 (2009).
   PubMed Web of Science ®Google Scholar
• Sakharova A, Dimaraki E, Chandler W, Barkan AL. Clinically silent somatotropinomas may be biochemically active. J. Clin. Endocrinol. Metab.90, 2117–2121 (2005).
   PubMedGoogle Scholar
• Yuen K, Cook D, Sahasranam P et al. Prevalence of GH and other pituitary hormone deficiencies in adults with nonsecreting pituitary microadenomas and normal serum IGF-1 levels. Clin. Endocrinol.69, 292–298 (2008).
   PubMed Web of Science ®Google Scholar
• Oyama K, Sanno N, Tahara S, Teramot A. Management of pituitary incidentalomas: according to a survey of pituitary incidentalomas in Japan. Semin. Ultrasound CT MR26, 47–50 (2005).
   PubMedGoogle Scholar
• Miyai K, Icinhare K, Kondo K, Nomi S. Asymptomatic hyperprolactinaemia and prolactinaemia in the general population. Mass screening by paired assays of serum prolactin. Clin. Endocrinol.25, 549–554 (1986).
   PubMed Web of Science ®Google Scholar
• Miyake A, Ikegami M, Chen CF et al. Mass screening for hyperprolactinemia and prolactinoma in men. J. Endocrinol. Investig.11, 383–384 (1988).
   PubMedGoogle Scholar
• Randall RV, Laws ER Jr, Abboud CF, Ebersold MJ, Kao PC, Scheithauer BW. Transsphenoidal microsurgical treatment of prolactin-producing pituitary adenomas. Results in 100 patients. Mayo Clin. Proc.58, 108–121 (1983).
   PubMed Web of Science ®Google Scholar
• Shy KK, McTiernan AM, Daling JR, Weiss NS. Oral contraceptive use and the occurrence of pituitary prolactinoma. J. Am. Med. Assoc.249, 2204–2207 (1983).
   PubMedGoogle Scholar
• Annegers JF, Coulam CB, Abboud CF, Laws ER Jr, Kurland LT. Pituitary adenoma in Olmstead County, Minnesota, 1935–1977: a report of an increasing incidence of diagnosis in women of childbearing age. Mayo Clin. Proc.53, 641–643 (1978).
   PubMed Web of Science ®Google Scholar
• Alexander L, Appleton D, Hall R, Ross WM, Wilkinson R. Epidemiology of acromegaly in the Newcastle region. Clin. Endocrinol.12, 71–79 (1980).
   PubMed Web of Science ®Google Scholar
• Bengtsson BA, Eden S, Ernest I et al. Epidemiology and long-term survival in acromegaly. Acta Med. Scand.223, 327–335 (1988).
   PubMed Web of Science ®Google Scholar
• Schneider HJ, Sievers C, Saller B, Wittchen HU, Stalla GK. High prevalence of biochemical acromegaly in primary care patients with elevated IGF-1 levels. Clin. Endocrinol. (Oxford)69, 432–435 (2008).
   PubMed Web of Science ®Google Scholar
• Demura H, Takeda R, Miyamori I et al. Cushing’s syndrome in Japan with special reference to adrenocortical nodular dysplasia or hyperplasia. Controversies in Disorders of Adrenal Hormones: Proceedings of the Open Symposium of Disorders of Adrenal Hormone. Takeda R, Miyamori I (Eds). Excerpta Medica Tokyo, Japan, Amsterdam, The Netherlands 3–25 (1988).
   Google Scholar
• Extabe J, Vazquez JA. Morbidity and mortality in Cushing’s disease: an epidemiological approach. Clin. Endocrinol.40, 479–484 (1994).
   PubMedGoogle Scholar
• Lindholm J, Jujul S, Jørgensen J et al. Incidence and late prognosis of Cushing’s syndrome: a population-based study. J. Clin. Endocrinol. Metab.86, 117–123 (2001).
   PubMed Web of Science ®Google Scholar
• Daneshdoost L, Gennarelli TA, Bashey HM et al. Identification of gonadotroph adenomas in men with clinically nonfunctioning adenomas by the luteinizing hormone subunit response to thyrotropin-releasing hormone. J. Clin. Endocrinol. Metab.77, 1352–1355 (1993).
   PubMed Web of Science ®Google Scholar
• Oppenheim DS, Kana AR, Sangha JS, Klibanski A. Prevalence of α-subunit hypersecretion in patients with pituitary tumors: clinically non-functioning and somatotroph adenomas. J. Clin. Endocrinol. Metab.70, 859–864 (1990).
   PubMedGoogle Scholar
• Buurman H, Saeger W. Subclinical adenomas in postmortem pituitaries: classification and correlation to clinical data. Eur. J. Endocrinol.154, 753–758 (2006).
   PubMed Web of Science ®Google Scholar
• Feldkamp Jm Santen R, Harms E et al. Incidentally discovered pituitary lesions: high frequency of macroadenomas and hormone-secreting adenomas – results of a prospective study. Clin. Endoccrinol. (Oxford)51, 109–113 (1999).
   PubMedGoogle Scholar
• Nishizawa S, Ohto S, Yokoyama T, Uemura K. Therapeutic strategy for incidentally found pituitary tumors (“pituitary incidentalomas”). Neurosurgery43, 1344–1348 (1998).
   PubMedGoogle Scholar
• Sanno N, Oyama K, Tahara S, Teramoto A, Kato Y. A survey of pituitary incidentaloma in Japan. Endocrinology149, 123–127 (2003).
   Google Scholar
• Wass J, Karavitaki N. Nonfunctioning pituitary adenomas: the Oxford experience. Nat. Rev. Endocrinol.5, 519–522 (2009).
   PubMedGoogle Scholar
• Honegger J, Zimmermann S, Psaras T et al. Growth modelling of non-functioning pituitary adenomas in patients refered for surgery. Eur. J. Endocrinol.158, 287–294 (2008).
   PubMedGoogle Scholar
• Davis P, Hoffman J, Tindall G, Braun I. CT surgical correlation in pituitary adenomas: evaluation in 113 patients. Am. J. Neuroradiol.6, 711–716 (1985).
   PubMedGoogle Scholar
• Johnson M, Hoare RD, Cox T et al. The evaluation of patients with a suspected pituitary microadenoma: computer tomography approximately magnetic resonance imaging. Clin. Endocrinol. (Oxford)36, 335–338 (1992).
   PubMedGoogle Scholar
• Kulkarni M, Lee K, McArdle C et al. MR imaging of pituitary microadenomas: technical considerations and CT correlation. Am. J. Neuroradiol.9, 5–11 (1988).
   PubMed Web of Science ®Google Scholar
• Connor S, Penney C. MRI in the differential diagnosis of a sellar mass. Clin. Radiol.58, 20–31 (2003).
   PubMed Web of Science ®Google Scholar
• Kaltsas G, Nomikos P, Kontogeorgos G, Buchfelder M, Grossman A. Clinical review: diagnosis and management of pituitary carcinomas. J. Clin. Endocrinol. Metab.90, 3089–3099 (2005).
   PubMed Web of Science ®Google Scholar
• Webb S, Ruscalleda J, Schwarzstein D et al. Computerized tomography versus magnetic resonance imaging: a comparative study in hypothalamic-pituitary and parasellar pathology. Clin. Endocrinol. (Oxford)36, 465 (1992).
   Google Scholar
• Aron DC, Kievit J. Adrenal incidentalomas.In: Endocrine Surgery. Schwartz AE, Pertsemlidis D, Gagner M (Eds). Marcel Dekker, NY, USA, 411–427 (2003).
   Google Scholar
• Mansmann G, Lau J, Balk E et al. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr. Rev.25, 309–340 (2004).
   PubMed Web of Science ®Google Scholar
• Turner H, Moore N, Byrne J, Wass J. Pituitary, adrenal and thyroid incidentalomas. Endocr. Relat. Cancer5, 131–150 (1998).
   Google Scholar
• AACE Acromegaly Guidelines Task Force. American assocation of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly. Endocr. Pract.10, 213–225 (2004).
   PubMedGoogle Scholar
• Casanueva F, Molitch M, Schlecjte J et al. Guidelines of the pituitary society for the diagnosis and management of prolactinomas. Clin. Endocrinol.65, 265–273 (2006).
   PubMed Web of Science ®Google Scholar
• Niemna L, Biller B, Findling J et al. The diagnosis of Cushing’s Syndrome: an endocrine society clinical practice guidelines. J. Clin. Endocrinol. Metab.93, 1526–1540 (2008).
   PubMedGoogle Scholar
• Aron DC. Clinical epidemiology and evidence-based endocrinology. Basic and Clinical Endocrinology. Greenspan FS, Gardner DG (Eds). McGraw-Hill Medical, Berkshire, UK (2007).
   Google Scholar
• Carroll T, Raff H, Findling J. Late-night salivary cortisol measurement in the diagnosis of Cushing’s syndrome. Endocrinol. Metab.4, 344–350 (2008).
   Google Scholar
• Kidambi S, Raff H, Findling JW. Limitations of nocturnal salivary cortisol and urine free cortisol in the diagnosis of mild Cushing’s syndrome. Eur. J. Endocrinol.157, 725–731 (2007).
   PubMed Web of Science ®Google Scholar
• Liu H, Bravata D, Cabaccan J, Raff H, Ryzen E. Elevated late-night salivary cortisol levels in elderly male Type 2 diabetic veterans. Clin. Endocrinol.63, 642–649 (2005).
   PubMed Web of Science ®Google Scholar
• Gibney J, Smith T, McKenna TJ. Clinical relevance of macroprolactiemia. Clin. Endocrinol. (Oxford)62, 633–643 (2005).
   PubMed Web of Science ®Google Scholar
• Molitch M. Medication-induced hyperprolactinemia. Mayo Clin. Proc.80, 1050–1057 (2005).
   PubMed Web of Science ®Google Scholar
• Catargi B, Rigalleau V, Poussin A et al. Occult Cushing’s syndrome in Type 2 diabetes. J. Clin. Endocrinol. Metab.88, 5808–5813 (2003).
   PubMed Web of Science ®Google Scholar
• Newsome S, Chen K, Hoang J, Wilson JD, Potter JM, Hichman PE. Cushing’s syndrome in a clinic population with diabetes. Intern. Med. J.38, 178–182 (2008).
   PubMedGoogle Scholar
• Nagai T, Imamura M, Misumi S, Mori M. Subclinical Cushing’s disease accompanied by malignant hypertension and diabetes mellitus. Intern. Med.41, 566–570 (2002).
   PubMedGoogle Scholar
• Contreras L, Cardoso E, Lozano MP et al. Detection of preclinical Cushing’s syndrome in overweight Type 2 diabetic patients. Medicina (B Aires)60, 326–330 (2000)
   PubMedGoogle Scholar
• Kievit J, Haak HR. Diagnosis and treatment of adrenal incidentaloma. A cost–effectiveness analysis. Endocrinol. Metab. Clin. North Am.29, 69–88 (2000).
   PubMedGoogle Scholar
• Woolf SH, Kamerow DB et al. Testing for uncommon conditions. the heroic search for positive test results. Arch. Intern. Med.150, 2451–2458 (1990).
   PubMedGoogle Scholar
• Mold, Stein. The cascade effect in the clinical care of patients. N. Engl. J. Med.314, 512–514 (1986).
   PubMed Web of Science ®Google Scholar
• Kassirer. Our stubborn quest for diagnostic certanity. A cause of excessive testing. N. Engl. J. Med.320, 1489–1491 (1989).
   PubMed Web of Science ®Google Scholar
• Ersoy R, Topaloglu O, Aydin C, Dirikoc A, Cakir B. Pituitary metastasis of breast cancer confirmed by fluorine-18 fluorodeoxyglucose positron emission tomography a case report. J. Endocrinol. Invest.30, 532–533 (2007).
   PubMedGoogle Scholar
• Ikeda H, Abe T, Watanabe K. Usefulness of composite methionine-positron emission tomography/3.0-tesla magnetic resonance imaging to detect the localization and extent of early-stage Cushing adenoma. J. Neurosurg. DOI: 10.3171/2009.7.JNS09285 (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Ryu S, Tafti B, Skirboll S. Pituitary adenomas can appear as hypermetabolic lesions in F-FDG PET imaging. J. Neuroimaging DOI: 10.1111/j.1552-6569.2008.00347.x (2009) (Epub ahead of print).
   Google Scholar
• Alzahrani A, Farhat R, Al-Arifi A, Al-kahtani N, Kanaan I, Abouzied M. The diagnostic value of fused positron emission tomography/computed tomography in the localization of adrenocorticotropin-secreting pituitary adenoma in Cushing’s disease. Pituitary12(4), 309–314 (2009).
   PubMedGoogle Scholar
• Suzuki M, Minenatsu T, Oyama K et al. Expression of proliferation markers in human pituitary incidentalomas. Endocrine Pathology17, 263–276 (2006).
   PubMed Web of Science ®Google Scholar
• Saeger W, Ludecke DK, Buchfelder M, Fahlbusch R, Quabbe H-J. Pathohistological classification of pituitary tumors: 10 years of experience with the German pituitary tumor registry. Eur. J. Endocrinol.156, 203–216 (2007).
   PubMed Web of Science ®Google Scholar
• Ferrante E, Ferrar M, Tristana C et al. Non-functioning pituitary adenoma data: a useful resource to improve the clinical management of pituitary tumors. Eur. J. Endocrinol.155, 823–829 (2006).
   PubMed Web of Science ®Google Scholar
• Drange MR, Fram NR, Herman-Bonert V, Melmed S. Pituitary tumor registry: a novel clinical resource. J. Clin. Endocrinol. Metab.85, 168–174 (2000).
   PubMed Web of Science ®Google Scholar
• Ramsey R. Evaluation of incidental findings on MRI of the central nervous system: part II. J. Insur. Med. (Seattle)37, 158–165 (2005).
   PubMedGoogle Scholar
• Ramsey R. Evaluation of incidental findings on MRI of the central nervous system: part I. J. Insur. Med. (Seattle)36, 167–173 (2002).
   Google Scholar
• Illes J, Kirschen M, Edwards E et al. Incidental findings in brain imaging research. Science311, 783–784 (2006).
   PubMed Web of Science ®Google Scholar
• Stone JH. Incidentalomas – clinical correlation and transslational science required. N. Engl. J. Med.354, 2748–2749 (2006).
   PubMedGoogle Scholar